November 10, 2026 · Nelson Marques, RD, CSSD
Creatine Forms: Monohydrate vs HCl vs Kre-Alkalyn vs Ethyl Ester — Why the Trial Literature Sits on One Form
The creatine category sells roughly a dozen branded forms — monohydrate, hydrochloride, Kre-Alkalyn (buffered), ethyl ester, nitrate, magnesium chelate, citrate, malate, pyruvate, orotate, AKG, liquid. The marketing claims escalate each new form on "better absorption," "no bloating," "no loading phase," "no gut side effects," or "stable in stomach acid." The published outcome literature — 700-plus controlled trials on muscle performance, power, hypertrophy, cognition, and rehabilitation — runs on one form: creatine monohydrate, almost always the Creapure-sourced material, at 3 to 5 g per day. Here is what each alternative form claims, what the direct head-to-head comparisons actually show against monohydrate, the physical-chemistry argument that explains why monohydrate wins at the dose level, and the four-question Supplement Facts read that catches the form-marketing premium.
Creatine Forms: Monohydrate vs HCl vs Kre-Alkalyn vs Ethyl Ester — Why the Trial Literature Sits on One Form
Walk the creatine aisle and the front labels run through roughly a dozen distinct forms — creatine monohydrate, creatine hydrochloride (HCl), Kre-Alkalyn (buffered creatine), creatine ethyl ester, creatine nitrate, creatine magnesium chelate, creatine citrate, creatine malate, creatine pyruvate, creatine orotate, creatine alpha-ketoglutarate (AKG), and various liquid creatine formulations. Each new form arrives at the retail shelf with a specific marketing claim — "better absorption," "no loading phase needed," "no bloating or water retention," "stable in stomach acid where monohydrate degrades," "superior solubility," "no gut side effects."
The published outcome literature on creatine runs to more than 700 controlled trials across resistance-training hypertrophy, high-intensity power output, repeat-sprint performance, cognitive outcomes, and clinical rehabilitation. The overwhelming majority of those trials — well above 95 percent, depending on how you count — used one form: creatine monohydrate, almost always the German-manufactured Creapure material, at a maintenance dose of 3 to 5 g per day following an optional 20 g per day loading phase for 5 to 7 days. The monohydrate form is the form the how-much-creatine-actually-works literature rests on.
Every alternative creatine form sold at the retail shelf has to answer two questions against that trial base. First, does the form deliver equivalent intramuscular creatine saturation against the monohydrate dose at a matched daily total? Second, if the form is priced at a premium against monohydrate on the basis of a marketing claim — better absorption, no loading, no bloating — do the direct head-to-head trials confirm the claim at the dose on the label?
The answer across every form the category has produced in the last 20 years is the same: the direct comparisons either show the alternative form is equivalent to monohydrate at a matched dose (not superior — equivalent) or show it is inferior at the dose the label supplies. No alternative form has produced a published outcome trial demonstrating superiority to monohydrate on any measured endpoint at a cost-adjusted dose. The form-marketing premium is a label number, not a trial outcome.
This is the same pattern that runs through the clinically studied ingredient vs clinically studied dose problem, the proprietary blends underdosing problem, and the 60-second supplement label read: the ingredient-identity claim on the front label is not the same claim as "this form at this dose produces the outcome the trial literature is cited for."
What Creatine Monohydrate Actually Is
Creatine itself is a nitrogenous organic compound — methylguanidino-acetic acid — synthesized endogenously in the liver, kidneys, and pancreas from the amino acids arginine, glycine, and methionine at a rate of roughly 1 to 2 g per day. Approximately 95 percent of total body creatine is stored in skeletal muscle as a mixed pool of free creatine (roughly a third) and phosphocreatine (roughly two-thirds). Phosphocreatine serves as the immediate phosphate donor for ATP regeneration during the first 10 to 20 seconds of maximal-effort exercise, and the size of the intramuscular phosphocreatine pool is the ceiling on sprint-and-power output across that time window.
Creatine monohydrate is creatine crystallized with one water molecule per creatine molecule, producing a white crystalline powder with roughly 88 percent elemental creatine by mass. A 5 g scoop of creatine monohydrate delivers approximately 4.4 g of elemental creatine. The Creapure-branded German-manufactured material dominates the clinical trial literature and holds a documented purity above 99.95 percent, with a controlled process that keeps dicyandiamide and dihydrotriazine byproduct levels below 50 ppm and 3 ppm respectively. Lower-cost monohydrate materials from Chinese manufacturers can carry higher byproduct levels and have not been evaluated in controlled trials to the depth that Creapure has.
The dose-response for creatine monohydrate on intramuscular creatine saturation is well characterized. A standard loading protocol of 20 g per day split into four 5 g doses for five to seven days elevates intramuscular total creatine from a baseline of approximately 125 mmol/kg dry muscle to approximately 155 mmol/kg dry muscle — a saturation ceiling that no dose or form has pushed above in published human work. The same ceiling is reached without a loading phase at a daily maintenance dose of 3 g per day across approximately 28 days. Loading accelerates saturation; it does not raise the endpoint.
The outcome signal at the saturated state reads as a 5 to 15 percent lift in high-intensity repeat-sprint output, a 5 to 10 percent lift in one-rep-max strength over 6-to-12-week resistance-training blocks, a 1 to 2 kg lean-mass increase over the same training window, and a modest but reliable improvement on cognitive outcomes under sleep deprivation or acute-stress conditions. Those are the signals the alternative forms have to match or beat.
Creatine Hydrochloride (HCl): The "Better Solubility, Lower Dose" Claim
Creatine hydrochloride is creatine complexed with hydrochloric acid, producing a form with substantially greater water solubility than monohydrate (approximately 38 g per 100 mL vs approximately 1.4 g per 100 mL for monohydrate) and a lower pH profile that the marketing claims pitch as "better gut absorption" and "no bloating."
The dominant retail dose for HCl runs at 750 mg to 1.5 g per day, with the marketing claim that the "superior absorption" allows the lower dose to match the effect of a standard 3-to-5 g monohydrate dose.
The physical chemistry does not support the claim. Creatine monohydrate is already well absorbed from the small intestine — bioavailability of oral creatine monohydrate is estimated at 95 to 99 percent at standard doses, with the remaining fraction accounting for the osmotic water draw that produces the mild GI side effects (bloating, loose stool) in a minority of users at the loading-phase dose. There is no absorption headroom for an alternative form to improve against the near-complete absorption the monohydrate already delivers at 3 to 5 g. The claimed "better absorption" would require that monohydrate is poorly absorbed, which it is not.
The head-to-head trial literature on HCl vs monohydrate is thin. The one published trial (Mendes 2017 — though it was a small 22-subject crossover design, not an outcome trial) matched HCl at 1.5 g/day against monohydrate at 3 g/day across a 4-week resistance-training protocol and reported no difference in strength or lean-mass outcomes between the two arms. The matched-dose comparison was not performed. No published trial has shown HCl at 1 g per day producing equivalent intramuscular creatine saturation or outcome signal against monohydrate at 3 to 5 g per day — the implicit claim of the lower-dose HCl marketing.
The clean read for the HCl form: it is an acceptable creatine source if dosed at the same elemental-creatine total as monohydrate (approximately 3 to 5 g per day of HCl, which delivers approximately 2.3 to 3.9 g elemental creatine — the HCl complex is roughly 78 percent creatine by mass). It is not an acceptable creatine source if dosed at 750 mg to 1.5 g per day on the marketing claim that the lower dose matches the full monohydrate effect. The 1 g HCl capsule at $35 for 30 servings is a pixie-dust creatine product priced at a 5-to-10x premium against the trial-anchored form.
Kre-Alkalyn (Buffered Creatine): The "Stomach Acid Stability" Claim
Kre-Alkalyn is a branded buffered creatine formulation — creatine monohydrate manufactured at a higher pH (approximately 12) with sodium carbonate and bicarbonate buffers, marketed on the claim that creatine monohydrate "degrades to creatinine in the stomach" and that the buffered form "protects the creatine through the gastric pH environment" for superior muscle delivery at a lower dose. The dominant retail dose runs at 1.5 to 3 g per day.
The underlying premise of the degradation claim is false. Creatine monohydrate is stable in aqueous solution at neutral and mildly acidic pH, and the degradation of creatine to creatinine in the stomach at physiological pH and typical gastric residence time (roughly 30 to 60 minutes) is approximately 1 to 2 percent of the ingested dose — a trivial loss. The conversion to creatinine is a slow dehydration reaction with a half-life measured in hours at pH 1 and in days at neutral pH. The claim that monohydrate "degrades on the way to the muscle" and requires buffering to survive gastric transit is not supported by the gastric-stability data.
The head-to-head trial literature on Kre-Alkalyn vs monohydrate is limited but informative. Jagim 2012 — the cleanest published comparison — ran Kre-Alkalyn at 1.5 g/day, Kre-Alkalyn at 5 g/day with a 7-day 20 g/day loading, and monohydrate at 5 g/day with a 7-day 20 g/day loading across a 28-day resistance-training protocol in 36 trained men. Intramuscular creatine content increased significantly in the monohydrate arm and the high-dose Kre-Alkalyn arm (both at 5 g/day matched dose) and did not increase in the low-dose Kre-Alkalyn arm (1.5 g/day). Strength and power outcomes followed the intramuscular-creatine trajectory. The trial directly tested the "lower-dose buffered creatine matches full-dose monohydrate" claim and the claim failed.
The clean read for Kre-Alkalyn: dosed at a matched elemental-creatine total against monohydrate (approximately 5 g per day of the buffered product), it is equivalent to monohydrate on outcomes. Dosed at the marketing-anchored 1.5 g per day, it is sub-threshold against the trial-anchored saturation protocol. The $40-per-bottle Kre-Alkalyn capsule at a 1.5 g daily dose is a premium-priced sub-trial dose of a form that offers no outcome advantage at matched dosing.
Creatine Ethyl Ester: The "No Water Retention" Claim
Creatine ethyl ester is creatine esterified with ethanol at the carboxylic acid group, producing a more lipophilic creatine derivative marketed on the claims of better membrane crossing, higher intramuscular uptake, lower dose requirement, and "no water retention or bloating" compared to monohydrate. The dominant retail dose runs at 2 to 4 g per day.
The chemistry works against the form. The ester bond on creatine ethyl ester is hydrolytically labile at the gastric and intestinal pH environment, with the molecule converting rapidly to creatinine (not back to creatine) under the acidic conditions of the stomach. The pharmacokinetic consequence is that oral creatine ethyl ester delivers less bioavailable creatine to the circulation than oral creatine monohydrate at a matched elemental dose — the form is less effective at delivering creatine to the muscle, not more.
The head-to-head trial literature is unambiguous. Spillane 2009 — the definitive head-to-head — ran creatine ethyl ester at 5 g/day following a 20 g/day loading protocol against monohydrate at the same dosing schedule across 47 days of resistance training in 30 men. The monohydrate arm elevated serum creatine, muscle total creatine, and strength/power outcomes significantly against placebo. The ethyl ester arm elevated serum creatinine (the degradation product) significantly without matching the monohydrate arm's intramuscular creatine increase or outcome signal. The trial demonstrated that creatine ethyl ester delivers creatinine to the kidneys, not creatine to the muscle, across the standard oral-dosing protocol.
The clean read for creatine ethyl ester: no published outcome trial supports the form. The chemistry of the ester bond under gastric pH makes the oral-delivery route mechanistically unsound. The form should be avoided regardless of the price point.
Creatine Nitrate, Magnesium Chelate, Citrate, Malate, Pyruvate, Orotate, AKG, and Liquid Forms
The remaining form category — nitrate, magnesium chelate, citrate, malate, pyruvate, orotate, AKG, and liquid — each arrives with a specific marketing claim (nitric oxide synergy, better solubility, ATP support, Krebs-cycle acceleration, bioavailability enhancement). Each form carries thin or no head-to-head trial literature against monohydrate at matched doses, and the clinical evidence base for the saturation-and-outcome signal remains anchored on the monohydrate form at the 3-to-5 g daily maintenance dose.
The one form worth a specific note is creatine magnesium chelate (Creatine MagnaPower), which has a small published trial base at matched elemental-creatine dosing against monohydrate and reports equivalent strength and lean-mass outcomes. The form is acceptable at matched dosing but carries no outcome advantage to justify the price premium.
The liquid creatine category is the clearest avoid. Creatine in aqueous solution degrades to creatinine over weeks at room temperature — a pre-dissolved liquid creatine product sitting on a store shelf for months before purchase has delivered an unknown fraction of its label creatine content as creatinine by the time it reaches the consumer. The powder forms (monohydrate, HCl, Kre-Alkalyn) are stable indefinitely at room temperature in sealed containers; the liquid forms are not.
The Multi-Ingredient Blend Problem
The creatine category also carries a proprietary-blend variant where creatine is listed as the first or second ingredient in a pre-workout, "ATP matrix," or "mass-gainer" blend at an unspecified per-serving dose. The 10-ingredient "creatine stack" proprietary blend at 5 g total blend weight that lists creatine monohydrate, creatine HCl, creatine nitrate, creatine AKG, creatine magnesium chelate, betaine, taurine, HICA, and a performance herb mix delivers an unknown fraction of its blend weight as any one creatine form. The individual creatine ingredients cannot be audited against the 3-to-5 g trial-anchored daily total.
The clean multi-ingredient exception is the pre-workout or recovery formula that discloses creatine monohydrate at 5 g per serving separately from the rest of the blend — the per-ingredient disclosure makes the creatine content auditable against the trial-anchored dose. The proprietary-blend format concealing the per-form creatine math is an implicit declaration that the formulator does not want the per-serving numbers audited.
The Four-Question 20-Second Supplement Facts Read
Pick up any creatine product and run four questions against the panel.
Question 1: Is the form specifically disclosed on the Supplement Facts panel? "Creatine Monohydrate" is a specific disclosure. "Creatine" or "Creatine Complex" without a specified form is not. The form determines which trial literature applies, and no specific form means no specific trial anchor.
Question 2: Is the per-serving dose at or above 3 g of elemental creatine? Monohydrate at 3 to 5 g per serving meets the trial-anchored maintenance dose. HCl at 3 to 5 g per serving meets it on an elemental-creatine basis. Any form at a per-serving dose below 2 g is below the saturation-maintenance threshold documented in the published literature. "Serving size: 1 capsule, Creatine 750 mg" is a sub-trial dose regardless of the form.
Question 3: Is the raw material source disclosed (Creapure for monohydrate, branded source for alternative forms)? Creapure monohydrate is the trial-material match. Branded alternative forms (Kre-Alkalyn, MagnaPower) at matched doses are acceptable. Unspecified-source materials have not been evaluated to the depth that Creapure has and may carry higher byproduct levels that affect the purity match against the trial literature.
Question 4: Is the creatine standalone or buried in a proprietary blend? A standalone creatine product with the form and dose disclosed is auditable. A proprietary blend listing creatine as an ingredient without the per-form, per-serving dose is not auditable, and the implicit math is almost always a sub-trial dose.
A creatine product that passes all four questions is a trial-anchored product regardless of the price point. A creatine product that fails on form, dose, source, or blend disclosure is a marketing product regardless of the brand on the front label. The trial literature has made the correct form clear; the retail shelf relies on the fact that most consumers have not read it.
SUBSCRIBE
Get more like this.
Evidence-based writing on supplements, performance nutrition, and the research behind what actually works. No spam, no daily emails — just the good stuff.
